Drug intelligence / Profile preview

SHR-1826 + fluorouracil + calcium folinate

Development stage: Unknown
Lead developer: Suzhou Suncadia Biopharmaceutical
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SHR-1826 + fluorouracil + calcium folinate is a **combination regimen** intended for cancer treatment, pairing SHR-1826, an **antibody-drug conjugate (ADC) targeting the c-Met receptor (hepatocyte growth factor receptor)**[1][7], with standard cytotoxic chemotherapy agents fluorouracil (5-FU) and calcium folinate (leucovorin). SHR-1826 is in clinical development for advanced solid tumors; its mechanism leverages tumor targeting via the anti-c-Met antibody, with intracellular release of a cytotoxic payload[1][7]. Fluorouracil is an antimetabolite inhibiting thymidylate synthase, disrupting DNA synthesis; calcium folinate enhances the binding of fluorouracil to its target, thereby increasing efficacy[2][4]. The combination is widely used for colorectal and other solid tumors, with calcium folinate modulating fluorouracil toxicity[2][4]. SHR-1826 is being developed by Suzhou Suncadia Biopharmaceuticals, with trials focused on advanced solid neoplasms[1][3][5][7].

Other names: SHR 1826 + 5-fluorouracil + leucovorin

Targets

TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on SHR-1826 + fluorouracil + calcium folinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1826 + fluorouracil + calcium folinate.

Explore the full profile